Open Access<p>The effects and mechanisms of a biosynthetic ginsenoside 3β,12β-Di-O-Glc-PPD on non-small cell lung cancer</p>
Author(s) -
Lulu Huang,
Ming Tang,
Qianqian Du,
Chunxia Liu,
Yan Chen,
Jin-Ling Yang,
Yan Li
Publication year - 2019
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s217039
Subject(s) - in vivo , angiogenesis , protein kinase b , cell growth , cancer research , pi3k/akt/mtor pathway , lung cancer , mapk/erk pathway , a549 cell , viability assay , chemistry , ginsenoside , western blot , pharmacology , cell , medicine , signal transduction , pathology , biology , biochemistry , ginseng , alternative medicine , microbiology and biotechnology , gene
A biosynthetic ginsenoside, 3-O-β-D-glucopyranosyl-12-O-β-D-glucopyranosyl-dammar-24-ene-3β, 12β, 20S-triol (C 3 C 12 PPD), showed antitumor activity against many tumor cells in vitro, especially had better anti-lung cancer activity than Rg3 in vitro and in vivo. However, the effects and molecular mechanisms of C 3 C 12 PPD on non-small cell lung cancer (NSCLC) remain unclear. According to previous studies, we hypothesized ginsenoside C 3 C 12 PPD could inhibit the tumor growth of NSCLC by targeting proliferation, migration and angiogenesis.